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Abstract 
 
Alzheimer’s disease (AD) is characterized by neurofibrillary tangles and extracellular amyloid-β 
plaques (Aβ). Despite ongoing research, some ambiguity remains surrounding the role of Aβ in 
the pathogenesis of this neurodegenerative disease. While several studies have focused on the 
mutations associated with AD, our understanding of the epigenetic contributions to the disease 
remains less clear. To that end, we determined the changes in DNA methylation in differentiated 
human neurons with and without Aβ treatment. We isolated the DNA from neurons treated with 
Aβ or vehicle, and digested the two samples with either a methylation-sensitive (HpaII) or a 
methylation-insensitive (MspI) restriction endonuclease. The fragments were amplified and co- 
hybridized to a commercial promoter microarray. Data analysis revealed a subset of genomic loci 
that shows a significant change in DNA methylation following Aβ treatment in comparison to  
the control group. After mapping these loci to nearby genes, we discovered high enrichment for 
cell-fate genes that control apoptosis and neuronal differentiation. Finally, we incorporated three 
of those genes in a possible model suggesting the means by which Aβ contributes to the brain 
shrinkage and memory loss seen in AD. 
 
 
Keywords: Alzheimer’s disease, DNA methylation, beta amyloid fragment (1-40), neurogenesis 
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Introduction 
 
Several lines of evidence suggest that epigenetic modifications, like DNA methylation, play a 
role in AD. First, late onset Alzheimer’s disease, which represents over 90% of AD cases, 
appears sporadic in nature with no known genetic cause [1]. Consistent with this, the inheritance 
pattern of AD in monozygotic twins suggests a non-Mendelian mode of acquiring the disease [2- 
4], indicating that DNA sequence alone does not explain AD development. Second, evidence of 
a parent-of-origin effect has been described for AD, identifying several genomic regions that are 
transmitted through the maternal line to affected individuals [5]. The requirement of an 
environmental contribution (in this case being the maternal germ line) is consistent with an 
epigenetic mechanism [6]. It is interesting to note that one of the most common mechanisms of 
parent-of-origin effects is “genomic imprinting” mediated by DNA methylation [7]. Third, 
studies in mice and humans suggest a global change in DNA methylation when comparing AD 
subjects to their control counterparts. In humans, monozygotic twins discordant for AD 
displayed differential DNA methylation levels in the anterior temporal neocortex, a region 
severely affected in AD [8]. The regions of the brain not affected by AD displayed identical 
DNA methylation levels, demonstrating the specificity of this result. The specific reduction of 
DNA methylation in the AD twin may provide a rationale for the link between folate deficiency 
and AD, since one of the normal functions of folate is to donate methyl groups for DNA 
methylation reactions [9]. Finally, the expression levels of several AD-associated genes (APP, β- 
APP cleaving enzyme, and neprylisin) are regulated based on the DNA methylation status of 
their respective promoters [10, 11]. It is important to note that although AD is associated with a 
global hypomethylation of the genome, the neprylisin (NEP) promoter actually becomes 
hypermethylated in murine cerebral endothelial cells treated with Aβ [11]. This evidence 
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demonstrates that a gene can be affected by an epigenetic change that increases or decreases its 
normal methylated state. NEP expression is significantly reduced in AD brains, most likely due 
to methylation-dependent silencing [11, 12]. Taken together, these data strongly suggest that 
DNA methylation plays a key role in the development of AD. 
The identification of epigenetic marks associated with AD development would provide 
excellent diagnostic markers for mapping AD progression and propose a novel, epigenetic model 
to how AD initially begins. In addition, a non-mutational, reversible process like DNA 
methylation would be vulnerable to the development of epigenetic therapeutics aimed at 
preventing or even undoing age-related changes to the genome. 
In order to determine if DNA methylation plays a role in AD, human IMR-32 cells were 
differentiated into mature neuronal cells and treated with Aβ. The methylation pattern of 
individual genomic regions was analyzed using genome-wide promoter arrays. Comparison of 
the methylation patterns before and after treatment identified the specific epigenetic changes that 
occur as neuronal development progresses toward an AD-like state. 
Several methods have been described for detection of the presence of methylated DNA. 
Bisulfite sequencing [13] utilizes the chemical differences between methylated and unmethylated 
cytosine. Sodium bisulfite reacts with normal cytosine (unmethylated) to form an intermediate 
easily deaminated to uracil. Sequencing will reveal a thymine at locations corresponding to 
unmethylated cytosines. Conversely, methylated cytosines are protected from the chemical 
transition to uracil, so no changes in the base sequence are detected (see [14] for review). 
Although reliable, this method is not easily adapted to meet the requirements of a genomic-sized 
examination since sequencing at this scale is quite expensive. 
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The methylated DNA immunoprecipitation (MeDIP) method [15] uses an antibody to 
capture DNA fragments by way of their methylated cytosines. The capture of specific regions is 
expressed as a purification enrichment and can be determined using PCR or by hybridizing the 
material to genomic chip arrays. The latter platform allows the global determination of 
methylated regions. Because this method does not detect unmethylated cytosines, a failure to 
detect a CpG region of interest could be due to its hypomethylated state or a technique problem 
in the purification process. 
Other methods of DNA methylation determination utilize the specificity of restriction 
endonucleases for a particular CpG methylation state (methylation-sensitive restriction enzyme; 
MSRE) followed by PCR analysis. An example of an MSRE is HhaI, which recognizes and cuts 
5’-GCGC-3’ sequences only when they are unmethylated [16]. PCR of the region will produce a 
visible product only when the included CpG is methylated and thus protected from enzymatic 
digestion. This assay requires additional PCR controls to determine if failed PCR runs are due to 
poor primer design or a truly hypomethylated region. 
This short coming can be resolved when two MSREs with different methylation 
sensitivities are used. For example, HpaII and MspI are isoschizomers that both recognize 5’- 
CCGG-3’ sequences. HpaII digestion is blocked when these sequences are methylated, while 
MspI is insensitive to the methylation status of the recognition site. When these fragments are 
cohybridized to genomic microarrays (described as HpaII tiny fragment Enrichment by 
Ligation-mediated PCR; or HELP assay), intergenomic and intragenomic comparisons 
 
concerning DNA methylation can be made [17]. Because this method can detect methylated and 
unmethylated regions on a genomic scale, the HELP assay was the method of choice for this 
study. 
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Methods and Methods 
 
Cell Culture 
Cholinergic IMR-32 human neuroblastoma cells [18] (ATCC) were grown and differentiated as 
previously described [19]. The cells were maintained in culture in proliferation medium [MEM 
with NEAA (Invitrogen 10370-0210, 2mM L-glutamine, 1mM sodium pyruvate, 10% FCS] at 
37°C in an atmosphere of 5% CO2. The cells were plated at a density of 5 × 105 cells/15 cm plate 
and grown for 48 hours in this proliferation media. The proliferation media was then replaced by 
differentiation media (proliferation medium with 2% FCS and 2mM sodium butyrate). The cells 
were maintained in differentiation media for 7 days then treated with either 25 µM Aβ1-40 peptide 
(Invitrogen 03-136) (prepared as described previously [11]) or vehicle for 48 hours. The cells 
were then rinsed with cold PBS (phosphate-buffered saline), harvested by scraping, pelleted by 
centrifugation in 1.5 ml Eppendorf tubes, and stored at -80°C. 
 
DNA Isolation and Digestion 
 
The undifferentiated, differentiated, and Aβ-treated cell pellets were thawed and kept on ice until 
they were treated with 478 µl of lysis buffer (0.5% SDS, 0.2M NaCl, 20mM EDTA), 20 µl 
protease K (2.5 mg/ml), and 2 µl RNase (10mg/ml). The reagents were mixed with the pellets by 
gentle agitation, and the tubes were incubated in a 42°C water bath overnight. Each sample was 
treated with 500 µl of phenol-chloroform-isoamyl alcohol (PCIAA) and incubated on a rotary 
wheel for 10 minutes at 37°C. The samples were then separated into an organic and aqueous 
layer by centrifuging at 17,000×g for 5 minutes. The aqueous layer containing the DNA in each 
sample was transferred to a new 1.5 ml Eppendorf tube. This process was repeated once to 
ensure DNA purity. To precipitate the DNA, 3× the sample volume in 100% ethanol was added 
to each sample, along with 1/10 the sample volume in 3M sodium acetate and .5 µl of glycogen 
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(20 mg/ml). The samples were then centrifuged at 17,000×g for 1 hour. The supernatant was 
removed, and the pellets were subsequently washed gently with 70% ethanol. The pellets were 
finally resuspended in 200 µl of deionized water. The DNA in each sample was then quantified 
using UV spectroscopy. 
Each sample was digested with HpaII and MspI in separate reactions according to the 
manufacturer’s recommendations. Each reaction contained 1 µg of DNA and either 4 µl of HpaII 
(10,000 U/ml) or 2 µl of MspI (20,000 U/ml) (New England Biolabs). The reactions were 
brought to a final volume of 200 µl with deionized water and incubated overnight at 37°C. The 
DNA from each sample was then purified as described above and resuspended in 15.5 µl of 10 
mM Tris-HCl (pH 8). 
Ligation-mediated PCR 
 
To avoid degradation or re-annealing of the overhangs, the ligation was performed immediately 
after the digestion. Two sets of adapters were used: NHpaII12 (5’-CGGCTTCCCTCG-3’), 
NHpaII24 (5’-GCAACTGTGCTATCCGAGGGAAGC-3’), JHpaII12 (5’-CGGCTGTTCATG- 
3’),   JHpaII24   (5’-CGACGTCGACTATCCATGAACAGC-3’).   The   24-mer   and   12-mer 
oligonucleotides of each set were annealed together in preparation for the ligation. Ligation was 
performed on HpaII and MspI-digested undifferentiated DNA, differentiated DNA, and Aβ 
DNA. Reactions were carried out in PCR tubes and consisted of 6 µl of 5× T4 ligase buffer 
(Invitrogen), 15.5 µl digested DNA, 4 µl of 50 µM pre-annealed JHpaII linkers, 4 µl of 50 µM 
pre-annealed NHpaII linkers, and 1 µl of T4 DNA ligase (4 U/µl). The reactions were put in a 
thermocycler at 16°C overnight. The reactions were then diluted to 10 ml by 10 mM Tris-HCl 
(pH 8). 
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The LM-PCR reactions contained 5 µl of HpaII-digested DNA or 2.5 µl of MspI-digested 
DNA, .5 µl of 100 µM JHpaII24 primer, .5 µl of 100 µM NHpaII24 primer, 25 µl of 2× SsoFast 
EvaGreen qPCR Supermix (Bio-Rad), and were brought to a final volume of 50 µl with 
deionized water. The MspI-digested DNA used in the amplification was half the volume of the 
HpaII-digested DNA. This is due to the difference in complexity of fragments in the MspI- 
digested DNA, which will cause these fragments to amplify and saturate the solution in the PCR 
faster and undergo “extra” cycles without amplification. This makes the sample susceptible to 
unwanted artifacts. The issue was circumvented by using half as much MspI-digested DNA as 
HpaII-digested DNA as was previously reported [17]. The LM-PCR scheme began with an initial 
extension step at 72°C for 10 minutes, 15-20 cycles of 95°C for 30 seconds and 72°C for 3 
minutes, and a final extension step at 72°C for 10 minutes. The reactions were purified using 
Qiagen’s QIAquick PCR Purification Kit (50) according to the manufacturer’s instructions, and 
DNA was quantified using UV spectroscopy. 
DNA microarrays and data analysis 
 
Five 385K DNA Methylation microarrays were purchased from Roche NimbleGen to hybridize 
2 undifferentiated DNA samples, 2 differentiated DNA samples, and 1 DNA sample from 
differentiated cells treated with Aβ. All samples were amplified by LM-PCR and purified to 
produce at least 4 µg of DNA with a concentration of at least 250 ng/µl. 
The raw microarray data from Roche NimbleGen was processed using Matlab 2011. 
 
First, correlation graphs were generated to examine the relationship between the 2 
undifferentiated DNA microarrays and between the 2 differentiated DNA microarrays. Each 
array contained 4,288 random probes designed by Roche NimbleGen for control purposes. The 
background fluorescence threshold was taken as 2.5 mean absolute deviations (MAD) above the 
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median fluorescence signal of the random probes [20, 21]. For a probe to be considered valid, the 
probe intensity from the MspI sample had to be above the threshold in all 5 arrays. An 
HpaII/MspI ratio histogram was generated for each condition (undifferentiated, differentiated, 
and Aβ-treated). The undifferentiated and differentiated data were an average of 2 microarray 
data sets for those conditions. All histograms were mean-centered, and the x-axis was converted 
from linear scale to log2. 
QPCR 
 
Site-specific qPCR confirmations were used to validate the microarray data and show their 
biological significance. DNA from IMR-32 cells was digested with HpaII and MspI in separate 
reactions as described above. An “uncut” control was included to serve as a positive control for 
maximum amplification possible. The recipe for the uncut digestion reaction was identical to that 
of MspI, except that 2 µl of 50% glycerol were added instead of the enzyme. The samples were 
subsequently purified as previously described and resuspended in 200 µl of deionized water. 
Primers were designed around the closest 5’-CCGG-3’ to a given probe using Primer3 
(http://frodo.wi.mit.edu/). The PCR product size range was chosen to be between 80-140 bp, the 
primer Tm was 60±2ºC, and the primer size was 20±2 bp. All other criteria were left as the 
default settings by the software. The 25 µl qPCR reactions contained .015-.025 µg of template 
DNA, 12.5 µl of 2x Supermix, and forward and reverse primers with a final concentration of 
.625 µM each. Reactions lacking DNA template were also included as control for primer self- 
annealing and amplification. Amplification was performed using a BioRad MJ Mini Personal 
Thermal Cycler. The touchdown qPCR scheme began with an initial melting step at 95°C for 5 
minutes. The first cycle was repeated 19 times and consisted of a melting step at 94°C for 10 
seconds, annealing step at 69°C for 30 seconds, and a final extension step at 72°C for 30 
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seconds. The annealing step decreased by 0.5°C each cycle. The second cycle followed 
immediately and consisted of a melting step at 94°C for 10 seconds, annealing at 59°C for 30 
seconds, and an extension step at 72°C for 30 seconds. This second cycle was repeated 24 times 
with a constant annealing temperature and was followed by a final extension step at 72°C for 5 
minutes. The amplification graphs were generated by BioRad CFX Manager 2.0. The 
quantification cycle (Cq) values were obtained for all samples and used for quantitation. 
Gene Ontology 
 
Gene symbols were linked to the 222 most changing regions (111 regions becoming 
hypomethylated and 111 regions becoming hypermethylated following Aβ treatment) using 
GREAT, a region/gene association and annotation software developed by Stanford University 
and Bejarano Lab [22]. Human genome 18 build was used for the species assembly, and the 
whole genome was used as the reference list. The resulting gene symbols were analyzed by 
GeneCodis, a gene annotation website for ontological assignments [23-25]. The gene symbols 
from three methylation categories (regions becoming hypomethylated, hypermethylated, and a 
random list) were analyzed using the following GeneCodis criteria: level 7 (the most stringent), a 
minimum of 3 genes associated with that ontology, and a chi-square value that was lower than 
the lowest obtained chi square value from the random list. The enrichment value from which the 
chi-square value was calculated by dividing the ratio of genes for a gene ontology in the list to 
the total number of genes in the list by the ratio of genes for that gene ontology in the genome to 
the total number of genes in the genome. 
Number of Genes for G.O. in List 
� Number of Genes in List � 
�   Total Number of Genes for G.O.  � Total Number of Genes in Genome 
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Results 
 
Global DNA Methylation Levels Remain Largely Unchanged After Aβ Treatment. 
 
In order to determine if DNA methylation plays a role in the development of AD, we set out to 
identify the methylation status of neurons before and after Aβ treatment. We utilized a 
microarray-based technique, known as the HELP assay, which compares the endonuclease 
efficiency of a methylation-sensitive enzyme (HpaII) versus a methylation-insensitive enzyme 
(MspI). These enzymes are isoschizomers that cleave the same 5’-CCGG-3’ palindrome. This 
recognition sequence contains a CpG dinucleotide that can serve as the target for de novo 
methylation by the DNMT3 family of methyltransferases. 
Analysis of the HpaII/MspI ratios before and after Aβ treatment revealed a bi-modal 
distribution of DNA methylation levels (Figure 1). In general, this distribution pattern 
represented groups of ratios that were hypermethylated or hypomethylated relative to the mean 
of all the ratios. Approximately 72.8% of the control ratios fell in the lower distribution 
(representing the high methylation fraction), while only 27.2% of the control ratios fell in the 
higher distribution (representing the low methylation fraction) (Figure 1A). A similar pattern was 
observed after Aβ treatment, with hypermethylated and hypomethylated fractions being 71.8% 
and 28.2% of the ratios, respectively (Figure 1B). The correlation of the control and Aβ -treated 
ratios was 0.978 (Figure 1B inset), demonstrating the global similarity of these samples. 
Interestingly, this correlation was slightly higher than the correlation between two independent 
control microarray samples (R = 0.9475; Supplemental Figure 1), indicating a higher variability 
in the control replicates than in the control to Aβ comparison. Overall, the Aβ treatment had no 
significant effects on the global DNA methylation levels in the neuronal cells. 
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Site-specific qPCR Confirms the Microarray Data. 
 
We then analyzed specific loci within our microarray data to determine if we could detect 
discrete levels of DNA methylation as indicated by the microarray data. For this purpose, we 
randomly chose genomic regions from the microarray dataset to examine the specific HpaII 
sensitivity by quantitative PCR. We chose regions that contained log2 HpaII/MspI ratios less than 
the mean for the hypermethylated distributions in order to detect high methylation levels (refer to 
Figure 1 - blue curves). We also chose regions that contained log2 HpaII/MspI ratios greater than 
the mean of the hypomethylated distributions to detect lower levels of DNA methylation (Figure 
1 - red curves). We then mapped all the 5’-CCGG-3’ sequences within the regions in order to 
design PCR primers to amplify across select restriction sites. Some regions only contained one 
restriction site (Figure 2A), while others contained many (Figure 2B and C). When we performed 
qPCR analysis of these particular 5’-CCGG-3’ sequences, we found that the site-specific results 
were aligned with the microarray data (Figure 2E-H). For example, two hypomethylated regions 
were chosen, ChrY:14100892 and Chr4:122212661 (Figure 2A and C), because they contained 
probes with log2 values greater than the average of the hypomethylation distribution in Figure 1A 
and B, respectively. QPCR analysis of a restriction site in these regions demonstrated low levels 
of amplification in the HpaII samples (Figure E and G). This indicates that HpaII is efficiently 
cutting these CpG-containing sequences; therefore, these sequences must not be heavily 
methylated. Since MspI can cut its restriction site regardless of CpG methylation, qPCR 
amplification of MspI-treated DNA should always be low and serves as a negative control. Two 
hypermethylated regions were also chosen, Chr16:67328870 and Chr15:94698105 (Figure 2B 
and D), because they contained probes with log2 values below the average of the 
hypermethylation distribution in Figure 1A and B, respectively. QPCR analysis of these regions 
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demonstrated much higher levels of amplification in the HpaII samples relative to the MspI 
controls (Figure 2F and H). This indicates that HpaII is relatively inefficient at cleaving these 
sites; therefore, these sequences must contain significant levels of DNA methylation. Taken 
together, our qPCR-based approach can determine sequence-specific DNA methylation levels 
that are consistent with the microarray-based data. 
Aβ Induces Significant Changes in DNA Methylation at a Subset of Genomic Locations.  
Since Aβ treatment did not affect neuronal DNA methylation levels on a global scale, we 
decided to focus our qPCR approach on the specific genomic loci that contained a significant 
change in their epigenetic ratio in relation to Aβ treatment. To this end, we subtracted the control 
microarray data from the Aβ-treated microarray data and plotted the log2 ratios as a histogram 
(Figure 3A). Ratios greater than zero indicated probes that were more hypomethylated in the Aβ 
condition, while ratios less than zero indicated probes that were more hypermethylated in the Aβ 
condition. Although the resulting data further demonstrates the similarity between the two 
datasets (85% of the data are within 1 STD), some regions of major change can be seen at the 
extremes of the plot (Figure 3B and C). These specific regions were of the greatest interest to us, 
since they represented significant epigenetic alterations as a result of Aβ treatment. We decided 
to focus our attention on these regions of greatest absolute change defined as the top 0.1% of all 
changing ratios (0.05% gaining methylation; 0.05% losing methylation). This translated into 111 
probes that gained methylation and 111 probes that lost methylation as neurons were exposed to 
Aβ, and corresponded to probe ratios exceeding 3 standard deviations from the average change 
of all probes. 
We decided to use our qPCR approach to test if, in fact, we could predict the methylation 
change at specific 5’-CCGG-3’ sequences based on the microarray data. We randomly chose 12 
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genomic regions from each 111 probe list and designed qPCR primers for two 5’-CCGG-3’ 
sequences in each region (named ‘upstream’ and ‘downstream’ in relation to the highest 
changing probe). As expected, microarray regions that gain methylation in the Aβ condition 
(Figure 4A and C; negative bars) contain 5’-CCGG-3’ sequences that are more difficult to cleave 
with HpaII when analyzed by qPCR (Figure 4B and D). Likewise, microarray regions that lose 
methylation in the Aβ condition (Figure 4E and G; positive bars) contain sequences that are more 
easily cleaved by HpaII when analyzed by qPCR (Figure 4F and H). Of all the 5’-CCGG-3’ loci 
tested, over 97% confirmed the microarray results (44 out of 45; Supplemental Figures 2 and 3). 
QPCR results from only 45 5’-CCGG-3’ loci of the 48 examined were kept since qPCR data 
from 3 regions contained bad primer pairs as indicated by their melting curves. It is interesting to 
note that both CpGs tested in a given region gave a similar result. This indicates that the 
methylation changes that occurred within a particular genomic region were not limited to a 
particular 5’-CCGG-3’ sequence, but rather were indicative of several other loci in the region as 
well. This is consistent with previous work that demonstrates the spreading of epigenetic marks 
and explains the similarity in our independent qPCR analyses within a region (i.e., the upstream 
and downstream qPCR results). 
Gene Ontology of Aβ-induced Epigenetic Changes Implicates Cell-Fate Pathways. 
 
We next wanted to determine if any of the regions that significantly change their DNA 
methylation status (i.e., increase methylation or decrease methylation) were associated with a 
particular cellular process. For this purpose, the genomic regions were mapped to the nearest 
transcription start site (TSS) using GREAT (http://bejerano.stanford.edu/great/public/html). 
Once duplicate gene symbols obtained from this software were removed, ontological 
assignments were determined using GeneCodis (http://genecodis.cnb.csic.es). Regions that lost 
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DNA methylation as a result of Aβ exposure were found near genes associated with 
neurogenesis, neuronal differentiation/development, and the negative regulation of apoptosis 
(Table 1). Regions that gained DNA methylation as a result of Aβ exposure were also found near 
genes associated with neurogenesis and apoptosis. These cellular pathways were specifically 
enriched in our Aβ-induced change lists, since a randomly generated gene list of similar size 
failed to produce ontological assignments with similar p-values. 
While some epigenetic changes were located over 10kb from the nearest TSS (e.g., 
DLX1), other changes were located at the promoter region (e.g., VHL). While DLX1 was 
identified because of a distal epigenetic change downstream of its TSS, it is interesting to note 
that it also contained a similar change proximal to its TSS, though the degree of change was not 
as great (Figure 5). Since our microarrays primarily focused on promoter proximal regions, it is 
not surprising that many epigenetic changes were found near genes (Supplemental Table 1). Of 
the regions that lost methylation, 45% were located within 5 kb from the nearest TSS, while only 
16% of the regions that gained methylation were in this promoter-proximal window 
(Supplemental Figure 4). Although this may indicate different mechanisms of epigenetic control, 
future genomic studies that do not contain a promoter bias will determine if Aβ-induced 
methylation changes have a preference for loci based on their distance from transcription start 
sites. 
As a whole, these results support the idea that AD pathology is produced, in part, by the 
epigenetic changes that occur within neurons as they age or are exposed to Aβ deposits. 
Although it is not known if these changes cause AD or are merely a result of AD progression, we 
believe these data further define AD as an epigenetic disease with specific cellular processes 
affected by altered methylation. 
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Discussion 
 
We can make three conclusions from the results presented herein. First, Aβ treatment of 
differentiated neurons in vitro does not change the global DNA methylation levels of the 
genome. There is an overall consistency in the distribution of methylation levels between the 
control sample and Aβ sample microarrays accompanied by a high correlation in probe values 
between these conditions. Second, exposure to Aβ leads to significant changes in methylation at 
a subset of loci, while others remain largely unchanged. Third, these significantly changing loci 
are associated with genes involved in neuronal differentiation, neurogenesis, and apoptosis 
control. Therefore, Aβ may contribute epigenetically to AD progression by propagating neuronal 
loss of function and death. This is quite significant since epigenetic modifications are reversible 
and might provide an avenue for the future treatment of AD. These modifications might also 
provide an epigenetic signature, indicative of the early genomic changes associated with AD. 
After mapping the microarray regions showing significant changes in methylation to 
nearby genes, we found that some regions were 70-300 bp away from the nearest genes, while 
others were more than 150,000 bp away. Although some of those regions are fairly distant from 
the nearest TSS, it is well-established that gene regulation can proceed distally through enhancer 
mechanisms (see [26, 27] for review). With this in mind, it would be interesting to determine if 
these distal changes actually define enhancer regions. It is also important to note that GREAT 
software maps input loci to the closest “canonical” TSS of a given gene, potentially ignoring 
closer TSS sites. In other words, some of the regions in our data may be closer to a nearby gene 
than the results seem to suggest. 
It is also important to utilize a better model for studying Aβ pathology, as a cancer-based 
model such as ours can introduce a background of methylation levels/patterns foreign to normal 
cells. For example, the hypomethylation peak seen in genome-wide DNA methylation profiles in 
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Figure 1A and B may be a remnant of the cancerous IMR-32 cell line from which our neurons 
were differentiated. This relatively large portion of genomic hypomethylation may be the result 
of long repetitive sequences becoming hypomethylated with cancer progression [28-30]. Current 
pilot studies using a mouse model system demonstrate a uniform distribution of methylation 
patterns, adding credibility to this hypothesis. Therefore, we expect future non-cancer based 
models to lack such a hypomethylated peak and be even more indicative of what occurs in an 
AD brain. 
Given the high enrichment in our gene ontology for cell-fate genes, we developed a 
coherent model outlining how Aβ possibly contributes to AD pathology by manipulating three 
such genes: DLX1, VHL, and PCNT. Previous work by Cobos et. al. shed light on the 
involvement of DLX transcription factors on the migration and differentiation of GABAergic 
interneurons [31]. Interestingly, they observed disruption in migration patterns and premature 
increase in neurite growth in interneurons of DLX1/2 double mutant mice. Their results 
demonstrated the importance of DLX1 and DLX2 in repressing neurite growth and maintaining a 
compact cell shape necessary for migration maneuvers. VHL, on the other hand, is a known 
tumor suppressor that is mutated in some neoplasms (see [32] for review). The third gene of 
interest, PCNT, is known for its involvement in the correct spindle assembly and metaphase 
progression during mitosis [33, 34], and some mutations in PCNT are associated with 
microcephaly [35]. Keeping in mind that Aβ causes significant hypomethylation of DLX1 and 
VHL and hypermethylation of PCNT as we saw, it is possible to suggest that Aβ promotes “de- 
differentiation” of normal neurons and prevents neuronal precursor cells from dividing and 
replacing the damaged cells (Figure 6). Such effects may contribute to the memory loss and 
aberrant brain morphology seen in AD. However, we present this model with some reservations; 
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although DNA methylation and demethylation have been traditionally associated with 
transcriptional repression and activation, respectively, some important exceptions have been 
reported [36-39]. Therefore, without mRNA transcription data, this model requires further 
support. 
Future studies utilizing in vivo models coupled with expression data will further clarify 
the effects of Aβ on neurons by monitoring the outcomes of differentially methylated genes. 
Hydroxymethylation is another emerging and interesting epigenetic modification that can 
possibly contribute to disease progression. Such experiments can focus on genes associated with 
differentiation and tumor suppression (such as DLX1 and VHL) and, in addition, evaluate the 
candidacy of Aβ-affected regions far apart from TSSs as distal enhancer regions. Combined with 
these efforts to confirm and supplement, our study promotes further exploration of AD from an 
epigenetic point of view. 
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Figure Legends 
 
Figure 1. Global DNA Methylation Distribution in Neurons Remains Largely Unchanged 
After Aβ Treatment In Vitro. 
The log2 HpaII/MspI ratios for the control and Aβ-treated microarray probes are plotted as 
frequency distributions. The data are mean-centered at zero (vertical grey line), with negative 
ratios and positive ratios signifying loci more and less methylated than the mean level of 
methylation, respectively. The blue and red curves represent the two components of the bimodal 
distribution. Each curve shows the probability of the data of each bin belonging to the left peak 
or the right peak of these bimodal distributions. (A) The mean HpaII/MspI ratios of the blue and 
the red curve are -0.66 and 1.76, respectively. (B) The mean HpaII/MspI ratios of the blue and 
the red curve are -0.76 and 1.95, respectively. 
Figure 2. Site-specific qPCR Confirms the Microarray Data. 
 
The landscapes of microarray regions selected for confirmations are plotted with purple bars 
representing the probe values. Triangles represent the 5’-CCGG-3’ sequences in those regions. 
The qPCR results for the chosen CCGGs (red triangles) are generated by setting the 2^(-(Cq)) of 
the MspI-digested DNA qPCR curve to “1” and setting the HpaII bar to represent the value of 
2^(-(CqHpaII-CqMspI)). 
Figure 3. Aβ Induces High Changes in Methylation Levels in a Subset of Loci. 
 
The data from the control microarray were subtracted from the Aβ-treated microarray data, and 
the result is plotted as a frequency distribution. The two dashed boxes represent the “upper” and 
“lower” 0.05% regions of all changing regions. A close-up frequency distribution of the “lower” 
0.05% of the probes with the highest decrease in HpaII/MspI ratio (B) and a close-up frequency 
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distribution of the “upper” 0.05% of the probes with the highest increase in HpaII/MspI ratio (C) 
are shown. 
Figure 4. Aβ-induced Probe Ratio Changes Correspond to CpG Methylation Changes. 
The landscapes of microarray regions selected for confirmations are plotted with purple bars 
representing the (Aβ - control) value for the probes. Triangles represent the 5’-CCGG-3’ 
sequences mapped to the region, with red triangles showing the specific CCGG sequences 
selected for qPCR analysis. Two separate sequences were chosen per region, one upstream and 
one downstream of the greatest changing probe. The “none” and “Aβ” bars in the qPCR graphs 
represent the value of 2^(-(CqHpaII-CqMspI)) in the control and Aβ sample DNA, respectively. 
Figure 5. Methylation Changes Occur at Promoter Proximal and Distal Regions. 
 
The microarray landscapes for two genes associated with neuronal differentiation (DLX1) and 
cell division (VHL) are shown. The landscapes demonstrate that Aβ-induced methylation 
changes can occur at regions proximal (VHL) or distal (DLX1) to the TSS (illustrated by a green 
arrow). Note that the x-axis has breaks to eliminate genomic gaps that do not contain probe data. 
Figure 6. An Epigenetic Model of Aβ Pathology. 
DLX1 protein is involved in repressing the dendrite and axon growth of neurons, preventing 
differentiation. By decreasing the methylation at DLX1, Aβ can increase the activity of this gene 
and promote the de-differentiation of mature neurons. Aβ also decreases the methylation near the 
VHL TSS, and increases methylation near the PCNT TSS; this consequently alters the 
expression profile of these genes. Given that VHL is a tumor suppressor and PCNT is a director 
of mitotic spindle assembly, such methylation changes may eventually prevent neuronal 
precursor cells (NPCs) from dividing and replacing the damaged cells. Put together, these 
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alterations decrease the number of functional neurons and may eventually result in the loss of 
memory and brain mass seen in Alzheimer’s disease. 
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Supplemental Figure Legends 
 
Supplemental Figure 1. Correlation of HpaII/MspI Ratios from Control IMR-32 Cells 
A scatter-plot of the probe ratios is shown comparing the microarray data from the individual 
control (untreated) replicates. The correlation coefficient was calculated using MatLab. 
Supplemental Figure 2. QPCR Confirmation of Regions with an Aβ-induced Methylation 
Increase 
Regions selected for ontological examination were randomly selected and subjected to qPCR 
analysis using differential enzyme digestion. The HpaII/MspI ratios were determined with higher 
ratios demonstrating a reduction in HpaII cutting efficiency. Higher ratios reflect an increase in 
5’-CCGG-3’ methylation and an increase in protection from HpaII digestion. The white and 
black bars in the qPCR graph represent the log10 value of 2^(-(CqHpaII-CqMspI)) in the control and 
Aβ sample DNA, respectively. Each region (X-axis) was analyzed twice using different primer 
sets as indicated by the two sets of bars per region. An asterisk indicates a region of study where 
the qPCR primers failed to work. 
Supplemental Figure 3. QPCR Confirmation of Regions with an Aβ-induced Methylation 
Decrease 
Regions selected for ontological examination were randomly selected and subjected to qPCR 
analysis using differential enzyme digestion. The HpaII/MspI ratios were determined with lower 
ratios demonstrating an increase in HpaII cutting efficiency. Lower ratios reflect an decrease in 
5’-CCGG-3’ methylation and a decrease in protection from HpaII digestion. The white and black 
bars in the qPCR graph represent the log10 value of 2^(-(CqHpaII-CqMspI)) in the control and Aβ 
sample DNA, respectively. Each region (X-axis) was analyzed twice using different primer sets 
as indicated by the two sets of bars per region. An asterisk indicates a region of study where the 
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qPCR primers failed to work. One region had a 5’-CCGG-3’ sequence that did not show a 
methylation decrease (indicated by a †). 
Supplemental Figure 4. Relative Gene Locations of Regions with Aβ-induced Methylation 
Changes 
The genomic regions with the greatest Aβ-induced methylation change were analyzed by 
GREAT to determine the distance to the transcription start site of nearby genes. A histogram of 
that distribution is shown with each bar representing the number of regions increasing (yellow) 
or decreasing (blue) their methylation status upon Aβ treatment. 
Supplemental Table 1. Significantly Changing Regions and Their Relative Distance from 
Nearby Genes 
An excel sheet of the GREAT output file is given showing the association of each genomic 
region to a specific gene symbol. The relative distance from the center of each genomic region to 
a nearby transcription start site (TSS) is shown in parenthesis. The methylation status change 
(loss or gain) is also indicated. 
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Figure 1. Global DNA Methylation Levels Remain Largely Unchanged After Aβ 
Treatment. 
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Figure 2. Site-specific qPCR Confirms the Microarray Data. 
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Figure 3. Aβ Induces Significant Changes in DNA Methylation at a Subset of Genomic 
Locations. 
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Figure 4. Aβ-induced Probe Ratio Changes Correspond to CpG Methylation Changes. 
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Table 1. Aβ Alters the DNA Methylation of Cell Fate Genes. 
 
 
 
 
 
Gene Set Gene Ontologya Genesb p-valuec Enrichment 
 
Genes Becoming 
 
Regulation of Neurogenesis; 
 
DLX1, DLX2 
 
0* 
 
192 
Hypomethylated CNS Neuron Differentiation    
(107 Genes)  
Neurogenesis; 
 
SOX9, NKX6-2 1.87x10-43 
 
61 
 CNS Development    
 Regulation of Nervous System MBP, ACCN1 1.02x10-21 38 
 Development    
 Negative Regulation of VHL, HAND2 1.91x10-17 30 
 Apoptotic Process    
 
Genes 
 
Brain Development 
 
PCNT, SKI 1.66x10-16 
 
29 
Becoming 
Hypermethylated 
 
Regulation of Apoptotic 
 
GAS6, LYST, 2.03x10-10 
 
18 
(77 Genes) Process ADAM8   
  DLL1, MAPK8IP3 7.89x10-10 13 
 Neurogenesis    
 
Randomd 
 
None 
 
>9x10-7 
 
NA 
(143 Genes)     
 
 
a Only ontologies that were considered relevant to the study are listed. 
b Genes found in several ontologies are not listed multiple times for clarity purposes. 
c The p-value for each gene set-ontology association was determined by GeneCodis using Chi- 
square tests. 
d A random list of regions was generated using MATLAB. This list was subjected to the same 
analysis as the list containing the changing regions. No gene ontologies were enriched to the 
same degree as the lowest ontology enrichment from the specific list. 
 
* The gene ontology p-value was displayed as zero due to limitations in the calculation input. 
The value was too low to be successfully determined, which suggests that it is <1.87x10-43 due 
to this p-value being successfully calculated. 
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Figure 5. Methylation Changes Occur at Promoter-proximal and Distal Regions. 
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Figure 6. An Epigenetic Model of Aβ Pathology 
 
 
36  
Aβ Alters DNA Methylation of Cell-Fate Genes 
 
 
 
Supplemental Figure 1. Correlation of HpaII/MspI Ratios from Control IMR-32 Cells 
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Supplemental Figure 2. QPCR Confirmation of Regions with an Aβ-Induced Methylation 
Increase 
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Supplemental Figure 3. QPCR Confirmation of Regions with an AB-Induced Methylation 
Decrease 
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Supplemental Figure 4.  Relative Gene Locations of Regions with Aβ-Induced Methylation 
Changes. 
 
 
40  
Aβ Alters DNA Methylation of Cell-Fate Genes 
 
Gene 
Symbol 
 
Changing Region (distance to TSS) 
AB-induced 
Change 
ABCC5 chr3:185217681-185219221 (-30) Loss of methylation 
ABCG1 chr21:42527874-42528575 (+15889) Loss of methylation 
ABHD6 chr3:58197548-58199404 (+177) Loss of methylation 
ACCN1 chr17:29507738-29508738 (-300) Loss of methylation 
ACP6 chr1:145608466-145610038 (+6) Loss of methylation 
ANKLE2 chr12:131806082-131806782 (+42092) Loss of methylation 
ANO10 chr3:43637980-43639364 (-108) Loss of methylation 
ARFGAP2 chr11:46914026-46915276 (+240344) Loss of methylation 
ARID3A chr19:934527-935866 (+58160) Loss of methylation 
ASPSCR1 chr17:77545256-77546605 (+17216) Loss of methylation 
ATRIP chr3:48462421-48463585 (-219) Loss of methylation 
AWAT2 chrX:69198265-69200010 (-12625) Loss of methylation 
C10orf54 chr10:73202947-73204143 (-202) Loss of methylation 
C18orf62 chr18:71128507-71129207 (+139720) Loss of methylation 
C19orf29 chr19:3648693-3649393 (-71230) Loss of methylation 
C1QTNF8 chr16:1082316-1084088 (+3043) Loss of methylation 
C8orf30A chr8:145407887-145409553 (+32) Loss of methylation 
CDH13 chr16:81217278-81219314 (+217) Loss of methylation 
CEBPG chr19:38555648-38556850 (-200) Loss of methylation 
CENPJ chr13:24394588-24395818 (-118) Loss of methylation 
CMTM1 chr16:65156996-65158350 (-178) Loss of methylation 
DACT2 chr6:168513887-168514588 (-50987) Loss of methylation 
DHX40 chr17:54996867-54998139 (-165) Loss of methylation 
DIO3 chr14:100419019-100419719 (-678072) Loss of methylation 
DLX1 chr2:172667513-172670300 (+10453) Loss of methylation 
DLX2 chr2:172667513-172670300 (+6817) Loss of methylation 
E2F4 chr16:65782768-65783768 (-301) Loss of methylation 
EBF3 chr10:131576120-131576820 (+75611) Loss of methylation 
EIF4G1 chr3:185514249-185515987 (-547) Loss of methylation 
EPN3 chr17:45968821-45969521 (+4124) Loss of methylation 
EXOC3L chr16:65782768-65783768 (-1660) Loss of methylation 
F11 chr4:187529470-187530572 (+105909) Loss of methylation 
FAM18B2 chr17:15406976-15408370 (-103) Loss of methylation 
FLJ43860 chr8:142839591-142840292 (-253430) Loss of methylation 
FUBP3 chr9:132443980-132445317 (-132) Loss of methylation 
GLS2 chr12:55167668-55169248 (-10) Loss of methylation 
GLTP chr12:108767404-108768105 (+34921) Loss of methylation 
 
 
 
Supplemental Table 1. Significantly Changing Regions and Their Relative Distance from 
Nearby Genes 
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GRIN3B chr19:934527-935866 (-16240) Loss of methylation 
HAND1 chr5:154006880-154007581 (-169214) Loss of methylation 
HAND2 chr4:174664266-174664967 (+23336) Loss of methylation 
HMOX2 chr16:4464076-4466962 (-823) Loss of methylation 
HOXB5 chr17:44025521-44026902 (-110) Loss of methylation 
IFT140 chr16:1597101-1598101 (-302) Loss of methylation 
IGBP1 chrX:69198265-69200010 (-70905) Loss of methylation 
ING4 chr12:6642329-6643365 (-278) Loss of methylation 
INPP5A chr10:134354410-134355581 (+153653) Loss of methylation 
IQSEC1 chr3:12924512-12925212 (+59098) Loss of methylation 
IQSEC2 chrX:53300308-53301009 (+66588) Loss of methylation 
JARID1C chrX:53300308-53301009 (-29330) Loss of methylation 
JHDM1D chr7:139638566-139639267 (-115707) Loss of methylation 
KCNQ1 chr11:1699992-3143916 (-843) Loss of methylation 
KDELC2 chr11:107873708-107875121 (-46) Loss of methylation 
KIAA1890 chr8:2325222-2325923 (+928962) Loss of methylation 
LARP1 chr5:154006880-154007581 (-107851) Loss of methylation 
LDHC chr11:18389628-18390682 (-279) Loss of methylation 
LRP4 chr11:46914026-46915276 (-17999) Loss of methylation 
MBP chr18:72820002-72820702 (+153410) Loss of methylation 
METTL2A chr17:57854197-57855516 (-121) Loss of methylation 
MGMT chr10:131576120-131576820 (+421014) Loss of methylation 
MKRN1 chr7:139824758-139826571 (+106) Loss of methylation 
MRPL33 chr2:27847287-27848561 (-164) Loss of methylation 
MTNR1A chr4:187529470-187530572 (+183510) Loss of methylation 
MYOM2 chr8:2325222-2325923 (+345008) Loss of methylation 
MYOM2 chr8:2173367-2174068 (+193153) Loss of methylation 
NGDN chr14:23007937-23008937 (-301) Loss of methylation 
NKX6-2 chr10:134354410-134355581 (+94531) Loss of methylation 
NMB chr15:82977632-82978418 (+24781) Loss of methylation 
NMRAL1 chr16:4464076-4466962 (-622) Loss of methylation 
NPM1 chr5:170746602-170748260 (+28) Loss of methylation 
OR10J5 chr1:157772221-157773221 (-300) Loss of methylation 
OR11H1 chr22:14608025-14608726 (+221428) Loss of methylation 
PCBP3 chr21:45877482-45878832 (-216146) Loss of methylation 
PDSS2 chr6:107886688-107888248 (+4) Loss of methylation 
PGAM5 chr12:131806082-131806782 (+8923) Loss of methylation 
PIAS1 chr15:66132825-66134462 (+18) Loss of methylation 
PIP5K1C chr19:3648693-3649393 (+2402) Loss of methylation 
PRPF4B chr6:3965767-3967073 (-148) Loss of methylation 
PSMF1 chr20:1046444-1047670 (-183) Loss of methylation 
RCN1 chr11:32068466-32069853 (-107) Loss of methylation 
RIMBP2 chr12:129691556-129692257 (-123492) Loss of methylation 
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RP1L1 chr8:10486075-10486775 (+63602) Loss of methylation 
RPL32 chr3:12924512-12925212 (-67913) Loss of methylation 
SAP18 chr13:20611884-20613115 (-185) Loss of methylation 
SCAND2 chr15:82977632-82978418 (+2330) Loss of methylation 
SCRG1 chr4:174664266-174664967 (-107425) Loss of methylation 
SFRS8 chr12:130760787-130762407 (+9) Loss of methylation 
SH2D3C chr9:129573138-129574172 (+7078) Loss of methylation 
SLC19A1 chr21:45877482-45878832 (-91378) Loss of methylation 
SLC37A3 chr7:139638566-139639267 (+105863) Loss of methylation 
SMOC2 chr6:168513887-168514588 (-70642) Loss of methylation 
SMOC2 chr6:168679057-168679757 (+94527) Loss of methylation 
SMOC2 chr6:169166157-169167446 (+581922) Loss of methylation 
SOX9 chr17:67624419-67625866 (-3613) Loss of methylation 
SPAG8 chr9:35801889-35803059 (-215) Loss of methylation 
SPARCL1 chr4:88669330-88670330 (-151) Loss of methylation 
SPATA20 chr17:45968821-45969521 (-10257) Loss of methylation 
SSTR5 chr16:1082316-1084088 (+14332) Loss of methylation 
STRA13 chr17:77545256-77546605 (+28131) Loss of methylation 
STX2 chr12:129691556-129692257 (+197857) Loss of methylation 
TAF10 chr11:6589455-6590821 (-117) Loss of methylation 
TFF3 chr21:42527874-42528575 (+80550) Loss of methylation 
THBS2 chr6:168679057-168679757 (+716655) Loss of methylation 
THBS2 chr6:169166157-169167446 (+229260) Loss of methylation 
TMEM131 chr2:97716500-97717903 (+261584) Loss of methylation 
TOR2A chr9:129573138-129574172 (-36230) Loss of methylation 
TRPV4 chr12:108767404-108768105 (-12160) Loss of methylation 
TSHZ1 chr18:71128507-71129207 (+77138) Loss of methylation 
TSNARE1 chr8:142839591-142840292 (+642502) Loss of methylation 
TTC15 chr2:3361652-3363020 (-117) Loss of methylation 
UNQ9391 chr8:10486075-10486775 (+65934) Loss of methylation 
UQCC chr20:33463047-33464047 (-300) Loss of methylation 
VHL chr3:10157518-10158973 (-73) Loss of methylation 
YDJC chr22:20316285-20317285 (-2445) Loss of methylation 
ZAP70 chr2:97716500-97717903 (+20739) Loss of methylation 
ZFP36L1 chr14:68332743-68333743 (-3705) Loss of methylation 
ZNF195 chr11:3356513-3357691 (-111) Loss of methylation 
ZNF236 chr18:72820002-72820702 (+155248) Loss of methylation 
ZNF556 chr19:2839720-2840421 (+21738) Loss of methylation 
ZNF57 chr19:2839720-2840421 (-11893) Loss of methylation 
hCG_25025 chr14:100419019-100419719 (+51858) Loss of methylation 
AADAC chr3:153013750-153014750 (-301) Gain of methylation 
ADAM8 chr10:134948526-134949226 (-8514) Gain of methylation 
ADK chr10:75605649-75606828 (+25268) Gain of methylation 
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BATF3 chr1:210939083-210940750 (+33) Gain of methylation 
BEND7 chr10:13556112-13556812 (+28520) Gain of methylation 
BEND7 chr10:13553694-13554394 (+30938) Gain of methylation 
BEND7 chr10:13554962-13555662 (+29670) Gain of methylation 
C10orf93 chr10:134726320-134728529 (-121371) Gain of methylation 
C13orf16 chr13:111717249-111718290 (+946754) Gain of methylation 
C13orf28 chr13:111865817-111866940 (-212291) Gain of methylation 
C13orf3 chr13:20849155-20849855 (-200795) Gain of methylation 
C14orf180 chr14:103966949-103968654 (-149299) Gain of methylation 
C5orf45 chr5:179209213-179209913 (+8883) Gain of methylation 
C6orf70 chr6:170295849-170296860 (+402709) Gain of methylation 
C6orf89 chr6:36960817-36962087 (-166) Gain of methylation 
C8orf42 chr8:1250830-1253745 (-766957) Gain of methylation 
COMT chr22:18274383-18275428 (-34403) Gain of methylation 
DIP2A chr21:46626893-46629188 (-75277) Gain of methylation 
DLGAP2 chr8:1250830-1253745 (-184688) Gain of methylation 
DLL1 chr6:170295849-170296860 (+145267) Gain of methylation 
EXOC2 chr6:464079-466338 (+172900) Gain of methylation 
FAM70B chr13:113568450-113569450 (+82923) Gain of methylation 
GALNT2 chr1:228534950-228535650 (+265649) Gain of methylation 
GAS6 chr13:113568450-113569450 (+22037) Gain of methylation 
GLOD4 chr17:659688-660388 (-27741) Gain of methylation 
GNB1L chr22:18274383-18275428 (-52444) Gain of methylation 
GPR123 chr10:134726320-134728529 (-6998) Gain of methylation 
GPR133 chr12:129937778-129938478 (-66277) Gain of methylation 
GPR133 chr12:130736641-130737341 (+732586) Gain of methylation 
GRIP1 chr12:65358820-65359820 (-300) Gain of methylation 
GSTZ1 chr14:76856306-76857770 (-69) Gain of methylation 
GTPBP6 chrY:243871-244571 (-73334) Gain of methylation 
GTPBP6 chrX:243871-244571 (-73334) Gain of methylation 
IGF2R chr6:160309320-160447571 (+68325) Gain of methylation 
INPP5A chr10:134154101-134154801 (-46892) Gain of methylation 
IRF4 chr6:464079-466338 (+128457) Gain of methylation 
KCNK9 chr8:141040229-141040929 (-256098) Gain of methylation 
KCNQ1 chr11:1699992-3143916 (-843) Gain of methylation 
KIAA0649 chr9:137290223-137291050 (-220832) Gain of methylation 
KIF26A chr14:103966949-103968654 (+292989) Gain of methylation 
KLF6 chr10:3490104-3490804 (+327001) Gain of methylation 
LOC339047 chr16:16321059-16321760 (-11802) Gain of methylation 
LYST chr1:234113363-234114363 (-17020) Gain of methylation 
MAPK8IP3 chr16:1730186-1730887 (+34315) Gain of methylation 
METTL11A chr9:131290223-131290924 (-137682) Gain of methylation 
MFSD10 chr4:2926463-2927164 (-21247) Gain of methylation 
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MUC13 chr3:126136070-126137070 (-300) Gain of methylation 
MYST4 chr10:75605649-75606828 (-650146) Gain of methylation 
MYT1 chr20:62280214-62280915 (+14294) Gain of methylation 
NID1 chr1:234113363-234114363 (+181241) Gain of methylation 
NME3 chr16:1730186-1730887 (+31174) Gain of methylation 
NOMO3 chr16:16321059-16321760 (+87520) Gain of methylation 
NOP14 chr4:2926463-2927164 (+8102) Gain of methylation 
NXN chr17:659688-660388 (+169722) Gain of methylation 
OLFM1 chr9:137290223-137291050 (+183727) Gain of methylation 
PCMTD2 chr20:62280214-62280915 (-76927) Gain of methylation 
PCNT chr21:46626893-46629188 (+59577) Gain of methylation 
PGBD5 chr1:228534950-228535650 (+44690) Gain of methylation 
PITRM1 chr10:3490104-3490804 (-285451) Gain of methylation 
POMT2 chr14:76856306-76857770 (-68) Gain of methylation 
PPP2R3B chrX:243871-244571 (+23406) Gain of methylation 
PPP2R3B chrY:243871-244571 (+23406) Gain of methylation 
PPP2R4 chr9:131290223-131290924 (+377509) Gain of methylation 
PTPRN2 chr7:157940649-157942073 (+131818) Gain of methylation 
RAN chr12:129937778-129938478 (+15607) Gain of methylation 
RER1 chr1:2201880-2203741 (-110263) Gain of methylation 
RPH3AL chr17:56119-57232 (+145900) Gain of methylation 
RPH3AL chr17:252659-254674 (-51091) Gain of methylation 
SEPHS1 chr10:13556112-13556812 (-126176) Gain of methylation 
SEPHS1 chr10:13554962-13555662 (-125026) Gain of methylation 
SEPHS1 chr10:13553694-13554394 (-123758) Gain of methylation 
SFRS8 chr12:130736641-130737341 (-24597) Gain of methylation 
SGCA chr17:45597589-45598589 (-301) Gain of methylation 
SKI chr1:2201880-2203741 (+52817) Gain of methylation 
SLC22A1 chr6:160309320-160447571 (-84407) Gain of methylation 
SLC45A2 chr5:34020337-34021337 (-300) Gain of methylation 
SMEK2 chr2:55697771-55699053 (+205) Gain of methylation 
SMOC2 chr6:169051742-169052507 (+467245) Gain of methylation 
SOX1 chr13:111865817-111866940 (+96465) Gain of methylation 
SOX1 chr13:111717249-111718290 (-52144) Gain of methylation 
SPPL2B chr19:2298135-2300732 (+19805) Gain of methylation 
SQSTM1 chr5:179209213-179209913 (+29115) Gain of methylation 
STK32C chr10:134154101-134154801 (-182984) Gain of methylation 
TAF1A chr1:220829418-220830678 (-170) Gain of methylation 
THBS2 chr6:169051742-169052507 (+343937) Gain of methylation 
TMPRSS9 chr19:2298135-2300732 (-41350) Gain of methylation 
TNRC4 chr1:149960410-149961111 (-4847) Gain of methylation 
TRAPPC9 chr8:141040229-141040929 (+497281) Gain of methylation 
TTC32 chr2:19964485-19966025 (-30) Gain of methylation 
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VPS53 chr17:252659-254674 (+311179) Gain of methylation 
ZDHHC20 chr13:20849155-20849855 (+81918) Gain of methylation 
ZDHHC23 chr3:115148637-115150077 (-81) Gain of methylation 
ZNF511 chr10:134948526-134949226 (-23537) Gain of methylation 
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